Prodia's 2026 Outlook Remains Promising Amid Expansion Plans

Strategic Expansion into Stem Cell Therapy

PT Prodia Widyahusada Tbk (PRDA) is expected to maintain its promising outlook in 2026, driven by its strategic expansion into high-value medical services. The company's acquisition of a 30% stake in ProSTEM in June 2025 is seen as a significant growth catalyst ¹

Analysts from Provina Visindo and BRI Danareksa Sekuritas have expressed positive views on Prodia's future prospects. Indy Naila from Provina Visindo noted that the expansion into stem cell services post-acquisition will positively impact revenue and margins, albeit gradually ¹

Positive Long-term Growth Prospects

Abida Massi Armand from BRI Danareksa Sekuritas highlighted that Prodia's shift towards regenerative therapy services based on stem cells will drive the company's growth. While the net profit contribution from ProSTEM is expected to be moderate in 2026, the investment is considered a valuable long-term opportunity ²

The stem cell sector is recognized for its significant growth potential and is often referred to as the 'future of medicine'. ProSTEM is expected to achieve substantial net profit growth in the long term, making Prodia's investment a strategic move ²